<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03439995</url>
  </required_header>
  <id_info>
    <org_study_id>R01HL126176</org_study_id>
    <nct_id>NCT03439995</nct_id>
  </id_info>
  <brief_title>Goal of Open Lung Ventilation in Donors</brief_title>
  <acronym>GOLD</acronym>
  <official_title>Goal of Open Lung Ventilation in Donors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Donor Network West</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this study is to assess whether ventilation of deceased organ donors with&#xD;
      an open lung protective ventilatory strategy will improve donor lung utilization rates and&#xD;
      donor oxygenation compared to a conventional ventilatory strategy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Deceased organ donors are maintained on life support including mechanical ventilation during&#xD;
      the time between brain death and organ procurement. The optimal mode of mechanical&#xD;
      ventilation for deceased organ donors has not been definitively established. Since deceased&#xD;
      organ donors may develop atelectasis leading to impaired oxygenation, an open lung protective&#xD;
      ventilatory strategy with higher positive end expiratory pressure (PEEP), lower tidal volume&#xD;
      and recruitment maneuvers has been hypothesized to be beneficial. Favorable outcomes were&#xD;
      observed in a European clinical trial comparing open lung protective ventilation (OLPV) to a&#xD;
      conventional ventilatory strategy in terms of donor oxygenation and lung utilization for&#xD;
      transplantation (Mascia L et al, Journal of the American Medical Association 2010). However,&#xD;
      donor management procedures in Europe are much shorter in duration compared to the US and it&#xD;
      is not clear that these findings are generalizable to the US donor management environment.&#xD;
&#xD;
      The GOLD trial will test the effect of an OLPV strategy compared to conventional ventilation&#xD;
      (CV) in the US donor management environment. This multi center trial will enroll 400 brain&#xD;
      dead organ donors randomized into 1 of 2 treatment arms. After randomization, mechanical&#xD;
      ventilation will be protocolized according to treatment arm with one arm receiving control&#xD;
      ventilation (CV) utilizing standard Donor Network West (DNW) protocols and the other arm&#xD;
      receiving the OLPV strategy with higher positive end expiratory pressure (PEEP) and lower&#xD;
      tidal volume compared to CV. The primary outcomes is donor lung utilization for&#xD;
      transplantation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Trial no longer feasible&#xD;
  </why_stopped>
  <start_date type="Actual">July 9, 2018</start_date>
  <completion_date type="Actual">January 1, 2021</completion_date>
  <primary_completion_date type="Actual">January 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Enrolled donors will be randomly assigned to two different modes of mechanical ventilation for the duration of donor management</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Outcomes in donors and lung transplant recipients will be done by assessors who are blinded to ventilator treatment assignment</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Donor lung utilization rate</measure>
    <time_frame>during donor management period (usually 12-48 hours)</time_frame>
    <description>Percent of donor lungs procured and transplanted into recipient</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Donor lung utilization in likely donors</measure>
    <time_frame>during donor management period (usually 12-48 hours)</time_frame>
    <description>Percent of donor lungs used from donors with &lt; 50 pack year smoking, age &lt; 65, negative serologies, and no underlying chronic lung disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donor oxygenation</measure>
    <time_frame>during donor management period (usually 12-48 hours)</time_frame>
    <description>Change in donor arterial oxygen (PaO2) from enrollment to procurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donor static compliance of the respiratory system</measure>
    <time_frame>during donor management period (usually 12-48 hours)</time_frame>
    <description>Change in compliance of the respiratory system (in ml/cm H2O) from enrollment to procurement. Static compliance (Cstat) is calculated as Cstat = ΔV / Pplat - PEEP where V is the volume delivered by the ventilator, Pplat is the end-inspiratory plateau pressure and PEEP is the level of positive end expiratory pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donor radiographic atelectasis scoring</measure>
    <time_frame>during donor management period (usually 12-48 hours)</time_frame>
    <description>Change in chest radiograph atelectasis score from enrollment to procurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recipient primary graft dysfunction</measure>
    <time_frame>72 hours after transplant</time_frame>
    <description>International Society of Heart and Lung Transplantation grade 2 or 3 primary graft dysfunction in lung transplant recipient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recipient mortality</measure>
    <time_frame>30 days after transplant</time_frame>
    <description>Lung transplant recipient death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">154</enrollment>
  <condition>Brain Death</condition>
  <condition>Organ Donation</condition>
  <condition>Organ Transplant Failure or Rejection</condition>
  <arm_group>
    <arm_group_label>Open Lung Protective Ventilation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volume cycled assist control ventilation with tidal volume 8 cc/kg predicted body weight, PEEP 10 cm water (H2O), recruitment maneuvers every 8 hours and after any ventilator disconnect</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional Ventilation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Volume cycled assist control ventilation with tidal volume 10 cc/kg predicted body weight, PEEP 5 cm H2O, recruitment maneuvers after any ventilator disconnect</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Open lung protective ventilation</intervention_name>
    <description>Higher PEEP, lower tidal volume mechanical ventilation</description>
    <arm_group_label>Open Lung Protective Ventilation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conventional ventilation</intervention_name>
    <description>Lower PEEP, standard tidal volume mechanical ventilation</description>
    <arm_group_label>Conventional Ventilation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Brain death&#xD;
&#xD;
          -  Authorization for research&#xD;
&#xD;
          -  ≥13 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Arterial/Inspired oxygen ratio (PaO2/FiO2) ≤ 150 mmHg&#xD;
&#xD;
          -  PaO2/FiO2 ≥ 400 mmHg&#xD;
&#xD;
          -  BMI &gt; 40&#xD;
&#xD;
          -  Hepatitis B surface antigen positive&#xD;
&#xD;
          -  Hepatitis C positive&#xD;
&#xD;
          -  Failure to complete donation process&#xD;
&#xD;
          -  Hemodynamic instability&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lorraine B Ware, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Donor Network West</name>
      <address>
        <city>San Ramon</city>
        <state>California</state>
        <zip>94583</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Mascia L, Pasero D, Slutsky AS, Arguis MJ, Berardino M, Grasso S, Munari M, Boifava S, Cornara G, Della Corte F, Vivaldi N, Malacarne P, Del Gaudio P, Livigni S, Zavala E, Filippini C, Martin EL, Donadio PP, Mastromauro I, Ranieri VM. Effect of a lung protective strategy for organ donors on eligibility and availability of lungs for transplantation: a randomized controlled trial. JAMA. 2010 Dec 15;304(23):2620-7. doi: 10.1001/jama.2010.1796.</citation>
    <PMID>21156950</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 14, 2018</study_first_submitted>
  <study_first_submitted_qc>February 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2018</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Lorraine B. Ware</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Death</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

